All lobbying filings

MEHLMAN CONSULTING, INC.

Lobbying for THE CAMPAIGN FOR SUSTAINABLE RX PRICING · A coalition of organizations working on market-based solutions to drug pricing.

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2026 · District of Columbia · House · Senate · $90,000.00 income · posted Apr 17, 2026

Official filing document

Bills named in this filing 26

HR 3789
DTC Act of 2025
S 229
DTC Act of 2025
HR 1843
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
S 1032
Major Richard Star Act
S 1954
Biosimilar Red Tape Elimination Act
HR 5526
Biosimilar Red Tape Elimination Act
S 1095
Stop STALLING Act
S 2630
Saving NSF’s Workforce Act
HR 1262
Mikaela Naylon Give Kids a Chance Act
S 3014
Ensuring Timely Access to Generics Act of 2025
S 1414
Expedited Access to Biosimilars Act
S 1040
Drug Competition Enhancement Act
S 1041
Affordable Prescriptions for Patients Act
S 1096
Preserve Access to Affordable Generics and Biosimilars Act
S 1097
Interagency Patent Coordination and Improvement Act of 2025
HR 4570
Interagency Patent Coordination and Improvement Act of 2025
S 43
Skinny Labels, Big Savings Act
HR 6485
Skinny Labels, Big Savings Act
HR 3269
ETHIC Act
S 2276
ETHIC Act
HR 3160
PREVAIL Act
S 1533
A bill to amend title 38, United States Code, to make permanent and codify the pilot program for use of contract physic…
HR 3152
Patent Eligibility Restoration Act of 2025
S 1546
Patent Eligibility Restoration Act of 2025
S 1785
No Handouts for Drug Advertisements Act
HR 3010
No Handouts for Drug Advertisements Act

Lobbying activity 4

Medicare/Medicaid

Prescription drug pricing issues. Fair Accountability and Innovative Research Drug Pricing Act. H.R. 3789/S. 229 - The Drug-price Transparency for Consumers (DTC) Act of 2025..

Pharmacy

Prescription drug pricing issues. H.R. 1843/S. 1032 - Increasing Transparency in Generic Drug Applications Act. S. 1954/H.R. 5526 - Biosimilar Red Tape Elimination Act; S. 1095 - Stop Stalling Act S. 2630 - Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act H.R.1262 - Mikaela Naylon Give Kids a Chance Act. S. 3014 - Ensuring Timely Access to Generics Act of 2025 S. 1414 - Expedited Access to Biosimilars Act S. 1032/H.R. 1843 - Increasing Transparency in Generic Drug Applications Act

Patent abuse issues. S.1040 - Drug Competition Enhancement Act. S.1041 - Affordable Prescriptions for Patients Act. S.1096 - Preserve Access to Affordable Generics and Biosimilars Act. S. 1097/H.R. 4570 - Interagency Patent Coordination and Improvement Act of 2025. S. 43/H.R. 6485 - Skinny Labels, Big Savings Act. H.R. 3269/S. 2276 - Eliminating Thickets to Increase Competition (ETHIC) Act. H.R. 3160/s. 1533 - the Prevail Act. H.R. 3152/S. 1546 - Patient Eligibility Restoration Act.

Taxation/Internal Revenue Code

S. 1785/H.R. 3010 - The No Handouts for Drug Advertisements Act.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.